Clinical Trials · NCT06885736
LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- Dasman Diabetes Institute
- Enrollment
- 232
- Start date
- Aug 2025
- Locations
- 1 site, Kuwait
- Primary endpoint
- MRI measured quadriceps cross sectional area (CSA)